10 Best Penny Stocks to Buy Now - 1 of 10

 
 

bluebird bio (NASDAQ:BLUE)

Number of Upgrades from Top-Ranked Analysts
5 (in the last 90 days)
Consensus Rating
Hold
Rating Score
2.3
Ratings Breakdown
5 Buy Ratings, 6 Hold Ratings, 1 Sell Ratings.
Consensus Price Target
$5.87 (536.1% Upside)

About bluebird bio

bluebird bio logobluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
3/27/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$6.00
3/27/2024Wells Fargo & CompanyLower Price TargetEqual Weight ➝ Equal Weight$4.00 ➝ $3.00
3/19/2024WedbushLower Price TargetNeutral ➝ Neutral$1.72 ➝ $1.68
3/5/2024HSBCLower Price TargetReduce ➝ Reduce$2.31 ➝ $1.02
1/9/2024William BlairReiterated RatingMarket Perform
1/8/2024WedbushReiterated RatingNeutral$3.00
12/21/2023Bank of AmericaLower Price TargetBuy ➝ Buy$12.00 ➝ $5.00
12/15/2023Wells Fargo & CompanyLower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $5.00
12/12/2023Robert W. BairdLower Price TargetOutperform ➝ Outperform$10.00 ➝ $7.00
12/11/2023HSBCDowngradeHold ➝ Reduce
 

Protect Yourself While There’s Still Time … (Ad)

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.